Cargando…

Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain

PURPOSE: Adherence to disease-modifying treatments is essential in order to maximize the beneficial effects of treatment for multiple sclerosis (MS). There are numerous treatments that have been approved. Treatment selection is essential in patient adherence. In addition, patient preference plays an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morillo Verdugo, Ramón, Ramírez Herráiz, Esther, Fernández-Del Olmo, Raquel, Roig Bonet, Montserrat, Valdivia García, María
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388740/ https://www.ncbi.nlm.nih.gov/pubmed/30863016 http://dx.doi.org/10.2147/PPA.S187983

Ejemplares similares

Factors Associated with Therapeutic Adherence in Multiple Sclerosis in Spain
por: Soria, Cristina, et al.
Publicado: (2023)

Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain
por: Fernández, Oscar, et al.
Publicado: (2012)

Assessing Pharmacists’ Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis
por: Martínez-López, Iciar, et al.
Publicado: (2020)

Adherence to Disease-Modifying Therapies for Multiple Sclerosis
por: Higuera, Lucas, et al.
Publicado: (2016)

Evaluation of Patient Experience with a Model of Coordinated Telematic Pharmaceutical Care Between Hospital and Rural Pharmacies in Spain [Response To Letter]
por: Morillo-Verdugo, Ramón, et al.
Publicado: (2023)

Evaluation of Patient Experience With A Model of Coordinated Telematic Pharmaceutical Care Between Hospital and Rural Pharmacies in Spain: A Proof of Concept
por: Morillo-Verdugo, Ramón, et al.
Publicado: (2023)

Correction: Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain
por: Fernández, Oscar, et al.
Publicado: (2012)

Adherence to disease-modifying therapies in patients with multiple sclerosis
por: Kołtuniuk, Aleksandra, et al.
Publicado: (2018)

Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis
por: Zanga, Gisela, et al.
Publicado: (2021)

Psychosocial predictors of patient adherence to disease-modifying therapies for multiple sclerosis
por: Alosaimi, Fahad D, et al.
Publicado: (2017)

Concurrent Use of Comedications Reduces Adherence to Antiretroviral Therapy Among HIV-Infected Patients
por: Cantudo-Cuenca, Maria Rosa, et al.
Publicado: (2014)

Clinical Impact of the Capacity-Motivation-Opportunity Pharmacist-Led Intervention in People Living with HIV in Spain, 2019–2020
por: Morillo-Verdugo, Ramón, et al.
Publicado: (2022)

Adherence to Treatment in Patients with Rheumatoid Arthritis from Spain
por: Pombo-Suarez, Manuel, et al.
Publicado: (2021)

Use of an Early Disease-Modifying Drug Adherence Measure to Predict Future Adherence in Patients with Multiple Sclerosis
por: Kozma, Chris M., et al.
Publicado: (2014)

The Impact of Adherence to Disease-Modifying Therapies on Functional Outcomes in Veterans with Multiple Sclerosis
por: Rabadi, Meheroz H, et al.
Publicado: (2021)

Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review
por: Washington, Francesca, et al.
Publicado: (2021)

Association between multiple sclerosis disease severity and adherence to disease-modifying therapies
por: Burkhard, Adam, et al.
Publicado: (2021)

Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis
por: Earla, Jagadeswara R, et al.
Publicado: (2020)

Narrative Review of the Literature on Adherence to Disease-Modifying Therapies Among Patients with Multiple Sclerosis
por: Menzin, Joseph, et al.
Publicado: (2013)

Epidemiology of multiple sclerosis and vitamin D levels in Lanzarote, Canary Islands, Spain
por: Pérez-Pérez, Silvia, et al.
Publicado: (2019)

Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study
por: Fernández, O., et al.
Publicado: (2012)

Health Staff Perceptions of Hate Violence in Spain
por: Fernández de Castro, Patricia, et al.
Publicado: (2021)

Impact on healthcare resource utilization of multiple sclerosis in Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2017)

Drug–drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain
por: Cantudo-Cuenca, M. D., et al.
Publicado: (2021)

Predictors of Adherence to Multiple Clinical Preventive Recommendations among Adults with Diabetes in Spain
por: Jimenez-Trujillo, Isabel, et al.
Publicado: (2015)

Potential interactions between pangenotypic direct-acting antivirals and concomitant cardiovascular therapies in patients with chronic hepatitis C virus infection
por: Sicras-Mainar, Antoni, et al.
Publicado: (2020)

Behavioral aspects of nurse practitioners associated with optimal multiple sclerosis care in Spain
por: Saposnik, Gustavo, et al.
Publicado: (2021)

Direct and indirect costs of Multiple Sclerosis in Baix Llobregat (Catalonia, Spain), according to disability
por: Casado, Virginia, et al.
Publicado: (2006)

Tuberculosis treatment adherence and fatality in Spain
por: Caylà, Joan A, et al.
Publicado: (2009)

Adherence to Therapy in Patients with Multiple Sclerosis—Review
por: Kołtuniuk, Aleksandra, et al.
Publicado: (2022)

Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study
por: Hansen, Kerstin, et al.
Publicado: (2015)

Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study
por: McKay, Kyla A, et al.
Publicado: (2016)

Impact of Adherence with Disease-Modifying Therapies on All-Cause Mortality Rates Among Veterans with Multiple Sclerosis
por: Rabadi, Meheroz H., et al.
Publicado: (2022)

Correction: Predictors of Adherence to Multiple Clinical Preventive Recommendations among Adults with Diabetes in Spain
por: Jimenez-Trujillo, Isabel, et al.
Publicado: (2016)

Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies
por: Melamed, Esther, et al.
Publicado: (2020)

Ocrelizumab in Multiple Sclerosis: A Real-World Study From Spain
por: Sempere, Angel P., et al.
Publicado: (2021)

The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study
por: Beer, Karsten, et al.
Publicado: (2011)

Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis
por: Pardo, Gabriel, et al.
Publicado: (2022)

The Association Between Persistence and Adherence to Disease-Modifying Therapies and Healthcare Resource Utilization and Costs in Patients With Multiple Sclerosis
por: Pardo, Gabriel, et al.
Publicado: (2022)

Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data
por: Engmann, Natalie J, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g0u65j4ocrvre2fre589iu644p